Clinical Management of Type 2 Diabetes Inertia

Clinical inertia in type 2 diabetes refers to the failure to initiate or intensify therapy promptly in patients who are not meeting glycaemic or cardiovascular risk targets. This inertia arises from a complex interplay of patient, clinician and system factors, including competing clinical priorities, concerns about side effects, insufficient follow-up and limited access to multidisciplinary support. Consequences include prolonged exposure to hyperglycaemia or hypertension, with a heightened risk of microvascular and macrovascular complications. Effective management demands systematic monitoring of glycated haemoglobin (HbA1c), blood pressure and other risk markers; clear protocols for treatment intensification; and patient-centred education to support shared decision-making. Innovations such as telemedicine, algorithm-driven decision aids and artificial intelligence-based scenario simulations are being evaluated to reduce delays in therapy adjustment. Addressing inertia requires alignment of clinical workflows, enhanced interprofessional collaboration and embedded performance feedback loops, all tailored to diverse health-care settings worldwide.

Research from Nature Portfolio

One recent cohort analysis of hypertensive patients with type 2 diabetes revealed that fewer than one third underwent antihypertensive treatment intensification when blood pressure remained uncontrolled, while over 38 % experienced therapeutic inertia despite guideline recommendations. Ethnicity, baseline blood pressure and the number of existing antihypertensive agents were identified as predictors of inertia, underscoring the need for culturally sensitive interventions and decision support in primary care. This study highlights persistent gaps in the timely escalation of therapy and calls for targeted efforts to integrate risk stratification tools and clinician education within routine diabetes management.

Clinical Management of Type 2 Diabetes Inertia publication trend

The graph below shows the total number of articles in clinical management of type 2 diabetes inertia across all publications each year (not limited to Nature Index journals).

Technical terms

Therapeutic inertia: Failure to initiate or escalate treatment in a timely manner when therapeutic targets are unmet.

Treatment intensification: Addition or increase of medication dose to achieve clinical targets for glycaemic control or blood pressure.

Glycated haemoglobin (HbA1c): A biomarker reflecting average blood glucose over the preceding two to three months, used to guide diabetes treatment.

Retrospective cohort study: An observational design that analyses existing data to assess outcomes in groups defined by exposure or intervention.

Logic Learning Machine: A form of artificial intelligence that derives human-readable decision rules from data sets for predictive modelling.

References

1. Overcoming Therapeutic Inertia in Type 2 Diabetes: Exploring Machine Learning-Based Scenario Simulation for Improving Short-Term Glycemic Control. Machine Learning and Knowledge Extraction (2024).
2. Effectiveness of Telemedicine in Diabetes Management: A Retrospective Study in an Urban Medically Underserved Population Area (UMUPA). Informatics (2023).
3. Treatment intensification and therapeutic inertia of antihypertensive therapy among patients with type 2 diabetes and hypertension with uncontrolled blood pressure. Scientific Reports (2024).
4. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obesity and Metabolism (2017).